BCRX  Biocryst Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.09 (-0.85%)

Stability Price

Overvalued by 97.92%

Company Metrics

  • 0 P/E
  • 55.96 P/S
  • 10.02 P/B
  • -0.68 EPS
  • -229.93% Cash ROIC
  • 1.26 Cash Ratio
  • 0 / 0% Dividend
  • 927,018.00 Avg. Vol.
  • 755.02M Market Cap.

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Why BioCryst Pharmaceuticals, Inc. Shares Scorched Higher
Motley Fool - Apr 1, 2015
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a predominantly clinical-stage biotech company focused on developing novel small molecule drugs to treat varying diseases, scorched higher by as much as 12% in Wednesday's trading session ...
BioCryst Awarded BCX4430 Advanced Development Contract - MarketWatch
FBR & Co. Begins Coverage on BioCryst Pharmaceuticals (BCRX)
Dakota Financial News - Apr 23, 2015
BioCryst Pharmaceuticals, Inc. logo FBR & Co. initiated coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report released on Monday morning, TheFlyOnTheWall.
Buzz Stocks: Charter Communications, Inc., BioCryst Pharmaceuticals, Inc., and ...
Schaeffers Research (blog) - Mar 31, 2015
... BCRX's 10-day put/call volume ratio of 1.53 rests higher than 90% of all similar readings taken in the past year. Elsewhere, although short interest plunged 17% in the latest reporting period, it still accounts for a lofty 23.9% of BioCryst ...
Benzinga's Top #PreMarket Gainers - Benzinga
Top Gainers Pre-Market Trading – Charter Communications, Movado Group ... - FxPips.com
MLV Pounds the Table on BioCryst Pharmaceuticals, Inc.
Smarter Analyst - Mar 25, 2015
MLV analyst Vernon Bernardino was out pounding the table on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), reiterating a Buy rating and price target of $15, which represents a potential upside of 85% from where the stock is currently trading.
Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)
TheStreet.com - Apr 2, 2015
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
BioCryst Pharmaceuticals PT Set at $15.00 by Needham & Company LLC (BCRX) - Dakota Financial News
Needham & Company LLC Analysts Give BioCryst Pharmaceuticals a $15.00 ... - sleekmoney
Benzinga's Top Upgrades
Benzinga - Apr 20, 2015
Analysts at BTIG Research upgraded Synchrony Financial (NYSE: SYF) from Neutral to Buy. Synchrony Financial shares closed at $30.52 on Friday.
Stock Analysis on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
Markets Wired - Apr 9, 2015
[Globe Newswire] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)(TREND ANALYSIS) announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's development programs at the 14th Annual Needham ...
BioCryst Pharmaceuticals, Inc. Discloses Insider Transaction - Tricity State
BioCryst Pharmaceuticals Receives $16.12 Consensus Target Price from ... - Mideast Time
BioCryst Pharmaceuticals Upgraded to "Neutral" at Bank of America (BCRX)
Dakota Financial News - Apr 20, 2015
BioCryst Pharmaceuticals, Inc. logo Bank of America upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from an underperform rating to a neutral rating in a research note issued to investors on Monday, TheFlyOnTheWall.
Mid-Day Changers: Luxottica Group SpA (LUX), BioCryst Pharmaceuticals, Inc ... - WallStreet Scope
Earnings Peek: BioCryst Pharmaceuticals Likely To Beat Estimates (BCRX)
Seeking Alpha (registration) - Jan 27, 2015
BioCryst Pharmaceuticals (NASDAQ:BCRX) is a small biotechnology company with a market cap of $814 million. It develops novel small molecule drugs that block key enzymes involved in orphan and infectious diseases.
BioCryst Pharma (BCRX) Granted Orphan Drug and Fast Track Status from the ... - Wall Street Pit
FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary ... - GlobeNewswire (press release)
Review on Stocks On The Dive - BioCryst Pharmaceuticals, Inc. (NASDAQ ...
wsnewspublishers - Mar 24, 2015
On Monday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals VP Sells $122986.80 in Stock (BCRX) - sleekmoney
Closing Bell Reports: BioCryst Pharmaceuticals, Inc. (BCRX), Zillow Group, Inc ... - WallStreet Scope